This finding aligns with a prior study, which demonstrated that targeting BCL-xL specifically with the BH3 mimetic enhanced the efficacy of docetaxel in a metastatic breast cancer xenograft model using MDA-MB-231 (LC3) cells14. The gene discussed is BCL2L1; the disease is breast cancer.